Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

PHASE4CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions
Giant Cell Tumor of Bone
Interventions
DRUG

Denosumab

120 mg administered subcutaneously (SC) every 4 weeks (Q4W).

Trial Locations (14)

2050

Royal Prince Alfred Hospital, Camperdown

10003

Mount Sinai Beth Israel Downtown, New York

19106

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

20010

Washington Cancer Institute at MedStar Washington Hospital, Washington D.C.

40136

Istituti Ortopedici Rizzoli, Bologna

55455

University of Minnesota Medical Center Fairview, Minneapolis

69373

Centre Leon Berard, Lyon

90403

Sarcoma Oncology Research Center LLC, Santa Monica

94805

Institut Gustave Roussy, Villejuif

01-211

Instytut Matki i Dziecka, Warsaw

02-781

"Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie †Panstwowy Instytut Badawczy", Warsaw

07010

Hospital Universitari Son Espases, Palma de Mallorca

221 85

Skane Universitetssjukhus, Lund

B31 2AP

Royal Orthopaedic Hospital, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03301857 - Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | Biotech Hunter | Biotech Hunter